PDA Releases Report on Passive Thermal Protection Systems
The PDA report discusses qualification and operational handling of passive thermal protection systems.
The Parenteral Drug Association (PDA) has released Technical Report No. 72, Passive Thermal Protection Systems for Global Distribution: Qualification and Operational Guidance (TR 72). The report discusses the qualification and operational handling of passive thermal protection systems (TPS) for temperature-controlled distribution of pharmaceutical and biological products. The report provides guidance regarding the materials used in the manufacture of TPS, as well as their characteristics and capabilities. It also gives guidance on the qualification approach, operational use and reuse, and options for recycling at the end of the systems’ life.
According to PDA, many factors play into the decision to use a passive system versus an active system. TR 72 assists “stakeholders in the supply chain to preserve the quality, safety, and efficacy of pharmaceutical and biological products during distribution,” said PDA in a press release.
Source: PDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
